Islet transplants are emerging as a viable option for the treatment of type 1 diabetes mellitus. From 1989 to 1995 we conducted a series of simultaneous islet-kidney transplants in six uremic type 1 diabetic patients. We report two of these patients who have shown persistent islet graft function over many years. Two female patients with duration of diabetes of 27 and 37 years underwent simultaneous islet-kidney transplant under steroid-and cyclosporine-based immunosuppression. Freshly isolated islets were supplemented with cryopreserved islets from our low-temperature bank of frozen islets. A total islet mass of 9,866 and 15,061 islet equivalents/kg body weight, respectively, was transplanted into the liver through portal vein. Reasonable blood glucose control has been achieved for up to 6 years posttransplant in one patient, but there was minimum clinical benefit from the islet graft at 10 years. In contrast, sustained insulin secretion with nearly normal HbA1c at 13 years follow-up was observed in another patient, providing hope for improving longterm graft outcomes for islet transplant recipient.
INTRODUCTION
islet graft function. It is the aim of this report to present the current follow-up on these two individuals. Simultaneous pancreas-kidney transplant in type 1 diabetic patients has excellent results and makes it possi-SUBJECTS AND METHODS ble for the patient to be insulin and dialysis free for the Patients long term. Simultaneous islet-kidney transplantation would be alternative option for treatment in uremic type
The two patients had type 1 diabetes confirmed by serum C-peptide levels less than 0.1 nmol/L after a 12-1 diabetic patients. A recent study reported that the rate of insulin independence of 83% can be achieved in pa-h fast and 90 min after oral ingestion of 360 ml of Sustacal (Mead Johnson, Belleville, Ontario, Canada). Patient tents with a median follow-up of >2 years after simultaneous islet-kidney transplant (4) .
1 is a 35-year-old female who had onset of type 1 diabetes at the age of 8 years. Pretransplant complications From 1989 to 1995 we conducted a series of six simultaneous islet-kidney transplants, the results of which included renal failure, retinopathy, hypothyroidism, and hypertension. She was on continuous ambulatory perito-have been described previously (14-16), including those of one patient who achieved more than 2 years of insulin neal dialysis at the time of the transplant in April, 1992. She was taking insulin 1.30 U/kg daily and her HbA1c independence. Two other patients in this series who received transplants in 1992 and 1995 continue to exhibit was 5.6%. Patient 2, a 42-year-old female, had type 1 442 LAKEY ET AL. antilymphoblast globulin, and maintained with cyclosporine A (CsA), azathioprine, and prednisone. CsA was introduced on day 8 posttransplant (whole blood trough levtwo donors, for a total of 783,180 IE (15,061 IE/kg) els 300-400 ng/ml). Azathioprine was maintained at 2 with packed cell volume of 8.5 ml and purity of 62%. mg/kg/day and prednisone at 0.5-0.6 mg/kg/day. The An insulin secretory response against high-glucose stimprocedures for islet isolation (15) and cryopreservation ulation was observed during perifusion of both freshly (7) in this series of patients have been previously deisolated and cryopreserved islets in both cases ( Fig. 1 ). scribed.
The response of fresh islets for patient 2 was not as In Vitro Islet Assessment quick as those of other three preparations.
Before transplantation, samples of freshly isolated or
Metabolic Follow-Up cryopreserved islets were stained with dithizone for de-Graft functions of islets and kidney for patient 1 are termination of number and purity. The established method detailed in Figure 2 . She became insulin independent of reporting variable islet diameter to a standardized difrom days 155 to 166 and again from days 837 to 992 ameter of 150 µm was used (9). Purity was assessed by while maintaining a HbA1c from 6.2% to 6.5%. Since comparing the relative proportions of dithizone-positive her transplant she has maintained near normal glycemic and unstained tissue. Islet viability was assessed by meacontrol (mean HbA1c 5.9% over 13 years) without sesuring insulin secretory response during perifusion with vere hypoglycemic episodes. At 5 years posttransplant, glucose 2.8 and 27.5 mmol/L. her renal function deteriorated and the kidney biopsy Metabolic Follow-Up showed histologic changes compatible with chronic rejection, without concomitant signs of CsA nephropathy. Data to assess the function of transplanted islets in-This necessitated a second kidney transplant in Novemcluded exogenous insulin requirements, HbA1c levels, ber, 1997. At 13 years posttransplant her HbA1c was and basal and stimulated (with 360 ml of Sustacal) glu-6.5% and she was on insulin 0.31 U/kg/day. Her Ccose and C-peptide levels.
peptide levels have slowly decreased over time and at RESULTS 13 years her basal and stimulated C-peptide levels were Islet Grafts Islet donor characteristics for each recipient are 0.17 and 0.33 nmol/L, respectively. In patient 2, reason-dent, returned to exogenous insulin therapy (15) . It is also known, however, that the majority of recipients able blood glucose control has been achieved for up to 6 years posttransplant ( Fig. 3) . Thereafter, her blood glu-given fresh islets lose partial graft function over time (12). We are not certain what the contribution of cryo-cose control has been deteriorating. At 10 years posttransplant her HbA1c was 11.8% and she was taking preserved islets with regard to long-term insulin secretion is in our two recipients. The episode of kidney re-0.75 U/kg/day of insulin. Basal and stimulated C-peptide levels at 10 years were 2.37 and 2.43 nmol/L, respec-jection in patient 1 suggests that her fresh islet graft from the same donor as the kidney had been rejected or tively. These values might be high due to reduced renal clearance of C-peptide, arising from declining renal func-subjected to alloimmune destruction. There are augments as to whether dissynchronous rejection exists in tion. simultaneous pancreas-kidney transplantation (8,10), DISCUSSION but isolated rejection seems to be a rare event (3). So we speculate a significant contribution of cryopreserved One of the keys to a successful outcome is the transplantation of an adequate number of viable islets. In the islets, which shared only one antigen with fresh islet in three donors and two in two donors, to her long-term two patients described here, the transplant islet mass was 9,866 and 15,061 IE/kg, using a combination of freshly glycemic control. Long-term graft function after allogeneic islet trans-isolated islets from one donor supplemented with cryopreserved islets from five and two pancreases, respec-plant is preserved only in a minority of cases. The reasons for this are yet to be fully understood, but are likely tively. Several cases with long-term graft function (defined as positive C-peptide secretion) were reported. multifactorial, including both immunologic causes and nonimmunologic components of graft dysfunction such Ferreira et al. (2) described sustained serum C-peptide secretion for up to 9 years after islet transplantation in as environment at heterotopic sites, direct toxicity on beta cells by immunosuppresive drugs, and abnormal two type 1 diabetic patients bearing an established kidney graft. Birkeland et al. (1) reported islet graft survival lipid metabolism in recipients (4). Patient 2 received a total of 15,061 IE/kg islets, of which 83% was freshly of greater than 6 years after simultaneous kidney-islet transplant. All reported cases with long-term graft func-isolated islets. These fresh islets showed considerably poor insulin secretory response during in vitro perifusion tion, including ours, received at least 9,000 IE/kg of islets from multiple donors. study. This could be one of the reasons why patient 2 did not exhibit similar long-term graft function to patient Transplantation of cryopreserved human islets has not lived up to widespread success. It has been sug-1, in spite of receiving a larger islet mass. In our series of six simultaneous islet-kidney trans-gested that cryopreserved islets are more likely to suffer from a reduced islet mass and viability (6) . This might plants, we used steroid-and cyclosporine-based immunosuppressive therapy, which is currently no longer in be one of the reasons why recipients of supplemental cryopreserved islets, who were initially insulin indepen-vogue for islet transplantation (11, 13) . Recent trials us- ing steroid-free immunosuppression for simultaneous is-been achieved for up to 6 years posttransplant in one patient, but there was minimum clinical benefit from the let-kidney transplantation will hopefully show better long-term islet function (3) .
islet graft at 10 years. In contrast, sustained insulin secretion at 13 years follow-up was observed in another In summary, reasonable blood glucose control has 
